Literature DB >> 3064280

A selective review of recent North American long-term followup studies of schizophrenia.

T H McGlashan1.   

Abstract

North American outcome studies of schizophrenia conducted within the past quarter century are reviewed if their minimum average followup is 10 years and they meet at least some modern design criteria. Ten such investigations are described and summarized. Taken as a whole, they demonstrate that schizophrenia can be a chronic disease whose outcome on the average is worse than that of other major mental illnesses. It is associated with an increased risk for suicide, physical illness, and mortality. The schizophrenic process, however, is not relentlessly progressive, as originally described, but appears to plateau after 5-10 years of manifest illness. Overall, outcome is heterogeneous, but much of the variance can be linked to sample characteristics, including expressions of psychopathology (broad vs. narrow diagnostic criteria, subtypes, and comorbidity), dimensions of chronicity (length of manifest illness, treatment resistance, age of onset, and institutionalization), and other predictor variables (gender, marital status, socioeconomic status, physical setting, and premorbid health). Long-term followup studies have yet to demonstrate clearly any effect of treatment on the natural history of schizophrenia. Finally, these studies support a broad definition of schizophrenia.

Entities:  

Mesh:

Year:  1988        PMID: 3064280     DOI: 10.1093/schbul/14.4.515

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  74 in total

Review 1.  Improving outcome in schizophrenia: the case for early intervention.

Authors:  A K Malla; R M Norman; L P Voruganti
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

2.  Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project.

Authors:  Roman Kotov; Laura Fochtmann; Kaiqiao Li; Marsha Tanenberg-Karant; Eduardo A Constantino; Joan Rubinstein; Greg Perlman; Eva Velthorst; Anne-Kathrin J Fett; Gabrielle Carlson; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2017-08-04       Impact factor: 18.112

3.  Soteria Berne: an innovative milieu therapeutic approach to acute schizophrenia based on the concept of affect-logic.

Authors:  Luc Ciompi; Holger Hoffmann
Journal:  World Psychiatry       Date:  2004-10       Impact factor: 49.548

4.  Chronicity reconsidered: improving person-environment fit through a consumer-run service.

Authors:  M J Chinman; R Weingarten; D Stayner; L Davidson
Journal:  Community Ment Health J       Date:  2001-06

Review 5.  Antipsychotic treatment for late-life schizophrenia.

Authors:  Jeremy A Sable; Dilip V Jeste
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

Review 6.  Review of the operational definition for first-episode psychosis.

Authors:  Nicholas J K Breitborde; Vinod H Srihari; Scott W Woods
Journal:  Early Interv Psychiatry       Date:  2009-11       Impact factor: 2.732

7.  The stress process perspective and adaptation of people with schizophrenia--an exploratory study.

Authors:  Yves Lecomte; Céline Mercier
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-02       Impact factor: 4.328

8.  North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research.

Authors:  Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming Tsuang; Elaine F Walker; Scott W Woods; Robert Heinssen
Journal:  Schizophr Bull       Date:  2007-01-25       Impact factor: 9.306

9.  Rationale and parameters for medication-free research in psychosis.

Authors:  Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2006-02-03       Impact factor: 9.306

10.  Management of persons with co-occurring severe mental illness and substance use disorder: program implications.

Authors:  Robert E Drake; Kim T Mueser; Mary F Brunette
Journal:  World Psychiatry       Date:  2007-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.